E-LIB Suche - Ergebnisse für: Gubens, Matthew A.

1

Polygenic risk score for ulcerative colitis predicts immune..:

Middha, Pooja ; Thummalapalli, Rohit ; Betti, Michael J....
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

Biomarker-directed, pembrolizumab-based combination therapy..:

Gutierrez, Martin ; Lam, Wei-Sen ; Hellmann, Matthew D....
Nature Medicine. , 2023

Link: https://doi.org/10.1038/..

3

Survival outcomes for lung neuroendocrine tumors in Califor..:

Mulvey, Claire K ; Paciorek, Alan ; Moon, Farhana...
Endocrine-Related Cancer. 31 (2023) 1 - p. , 2023

Link: https://doi.org/10.1530/..

4

Osimertinib in NSCLC With Atypical EGFR-Activating Mutation..:

Ji, Jingran ; Aredo, Jacqueline V. ; Piper-Vallillo, Andrew...
JTO Clinical and Research Reports. 4 (2023) 3 - p. 100459 , 2023

Link: https://doi.org/10.1016/..

5

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors ..:

Benjamin, David J. ; Chen, Shuai ; Eldredge, Joanna B....
JTO Clinical and Research Reports. 3 (2022) 12 - p. 100427 , 2022

Link: https://doi.org/10.1016/..

6

Phase 1 Study of Ceritinib Combined With Trametinib in Pati..:

Lara, Matthew S. ; Gubens, Matthew A. ; Bacaltos, Bianca...
JTO Clinical and Research Reports. 3 (2022) 12 - p. 100436 , 2022

Link: https://doi.org/10.1016/..

7

Five Year Survival Update From KEYNOTE-010: Pembrolizumab V..:

Herbst, Roy S. ; Garon, Edward B. ; Kim, Dong-Wan...
Journal of Thoracic Oncology. 16 (2021) 10 - p. 1718-1732 , 2021

Link: https://doi.org/10.1016/..

8

Molecular Risk Stratification is Independent of EGFR Mutati..:

Woodard, Gavitt A. ; Kratz, Johannes R. ; Haro, Greg...
Clinical Lung Cancer. 22 (2021) 6 - p. 587-595 , 2021

Link: https://doi.org/10.1016/..

9

Changes in older adults' life space during lung cancer trea..:

Wong, Melisa L. ; Shi, Ying ; Smith, Alexander K....
Journal of the American Geriatrics Society. 70 (2021) 1 - p. 136-149 , 2021

Link: https://doi.org/10.1111/..

10

Pembrolizumab in combination with ipilimumab as second-line..:

Gubens, Matthew A. ; Sequist, Lecia V. ; Stevenson, James P....
Lung Cancer. 130 (2019) - p. 59-66 , 2019

Link: https://doi.org/10.1016/..

11

Phase II trial of single agent amrubicin in patients with p..:

Hellyer, Jessica A. ; Gubens, Matthew A. ; Cunanan, Kristen M....
Lung Cancer. 137 (2019) - p. 71-75 , 2019

Link: https://doi.org/10.1016/..

12

Adjuvant Chemotherapy Guided by Molecular Profiling and Imp..:

Woodard, Gavitt A. ; Wang, Sue X. ; Kratz, Johannes R....
Clinical Lung Cancer. 19 (2018) 1 - p. 58-64 , 2018

Link: https://doi.org/10.1016/..

13

Pembrolizumab and platinum-based chemotherapy as first-line..:

Gadgeel, Shirish M. ; Stevenson, James P. ; Langer, Corey J....
Lung Cancer. 125 (2018) - p. 273-281 , 2018

Link: https://doi.org/10.1016/..

14

OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular ..:

Woodard, Gavitt ; Crockard, Jane ; Zoon-Besselink, Clara...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S320 , 2017

Link: https://doi.org/10.1016/..

15

OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients w..:

Herbst, Roy ; Garon, Edward ; Kim, Dong-Wan...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S254-S255 , 2017

Link: https://doi.org/10.1016/..